Skip to Content

Join the 'Polymyalgia Rheumatica' group to help and get support from people like you.

Polymyalgia Rheumatica News

Related terms: Polymyalgia

Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke

Posted 28 Jul 2014 by Drugs.com

MONDAY, July 28, 2014 – A common inflammatory muscle disorder that causes pain and stiffness in older people may increase the risk for heart attack and stroke, new research suggests. A British study found that patients with polymyalgia rheumatica are more likely to develop vascular disease – conditions that affect the blood vessels. Doctors should carefully manage the vascular risk factors of patients with polymyalgia rheumatica to reduce their risk for complications, the study authors concluded. Unlike other inflammatory diseases such as rheumatoid arthritis and systemic lupus, the link between polymyalgia rheumatica and an increased risk for vascular disease has not been well-established. "Polymyalgia rheumatica is one of the most common inflammatory rheumatologic conditions in older adults," the study authors wrote. To date, evidence regarding the risk of vascular disease in ... Read more

Related support groups: Ischemic Stroke, Heart Attack, Polymyalgia Rheumatica, Myocardial Infarction

Horizon Pharma Announces FDA Approval of Rayos (prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications

Posted 31 Jul 2012 by Drugs.com

DEERFIELD, Ill., July 26, 2012 /PRNewswire/ – Horizon Pharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Rayos (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD). The FDA approval was supported by data bridging the pharmacokinetics of Rayos to immediate-release prednisone and data from the Circadian Administration of Prednisone in RA (CAPRA-1 and 2) trials. The CAPRA-2 trial demonstrated that people with moderate to severe RA treated with Rayos experienced a statistically significant improvement in ACR20 response criteria compared to placebo. The CAPRA-1 trial supported the overall safety of Rayos. "We are extremely pleased the ... Read more

Related support groups: Rheumatoid Arthritis, Prednisone, Asthma, Psoriatic Arthritis, Ankylosing Spondylitis, Polymyalgia Rheumatica, COPD

Ask a Question

Further Information

Related Condition Support Groups

Connective Tissue Disorders